Cardiovascular risk factors in adolescents

被引:15
作者
Gidding S.S. [1 ]
机构
[1] Nemours Cardiac Center, A. I. duPont Hospital for Children, Wilmington, DE 19803
关键词
Atorvastatin; Kawasaki Disease; Ezetimibe; National Cholesterol Education Program; Familial Hypercholesterolemia;
D O I
10.1007/s11936-006-0047-1
中图分类号
学科分类号
摘要
Most children who are normal weight for height and otherwise healthy have risk factor levels associated with the absence of heart disease (ie, they do not smoke, do not have diabetes, are physically active, have low-density lipoprotein levels < 110 mg/dL, and have blood pressure < 120/80 mm Hg). However, by adolescence, the earliest lesions in the atherosclerotic process, fatty streaks and raised lesions, are present in the coronary arteries and the abdominal aorta. The severity of early atherogenesis is related to the coexistence of the major cardiovascular risk factors. Most commonly, the associated risk disturbances are mild: borderline hypertension, mild dyslipidemia, insulin resistance, overweight, physical inactivity, and initiation of tobacco use. Rarely, more severe risk factors are present: familial hypercholesterolemia (a genetic disorder of lipid metabolism), diabetes mellitus, secondary hypertension of long standing, or risk factors associated with chronic conditions such as end-stage renal disease. Thus, cardiovascular risk management in this age group has two components: primordial prevention (the prevention of the development of cardiovascular risk in the first place) and primary prevention (more aggressive treatment of identified risk factors in high-risk individuals either through behavioral or pharmacologic means). Trials beginning in adolescence of the primary prevention of atherosclerosis-related diseases have not been undertaken; thus, the decision to initiate pharmacologic management in high-risk adolescents requires careful thought. Copyright © 2006 by Current Science Inc.
引用
收藏
页码:269 / 275
页数:6
相关论文
共 23 条
  • [1] McMahan C.A., Gidding S.S., Fayad Z.A., Et al., Risk scores predict atherosclerotic lesions in young people, Arch Intern Med, 165, pp. 883-890, (2005)
  • [2] Wiegman A., Hutten B.A., de Groot E., Et al., Efficacy and safety of statin therapy in children with familial hypercholesterolemia: A randomized controlled trial, JAMA, 292, pp. 331-337, (2004)
  • [3] Parekh R., Gidding S.S., Cardiovascular complications in pediatric end-stage renal disease, Pediatr Nephrol, 20, pp. 125-131, (2005)
  • [4] Management of dyslipidemia in children and adolescents with diabetes, Diabetes Care, 26, pp. 2194-2197, (2003)
  • [5] Newburger J.W., Takahashi M., Gerber M.A., Et al., Diagnosis, treatment, and long-term management of Kawasaki disease: A statement for health professionals from the Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association, Circulation, 110, pp. 2747-2771, (2004)
  • [6] The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents, Pediatrics, 114, pp. 555-576, (2004)
  • [7] Highlights of the report of the Expert Panel on Blood Cholesterol Levels in Children and Adolescents, Pediatrics, 89, pp. 495-501, (1992)
  • [8] Daniels S.R., Arnett D.K., Eckel R.H., Et al., Overweight in children and adolescents: Pathophysiology, consequences, prevention, and treatment, Circulation, 111, pp. 1999-2012, (2005)
  • [9] Active and passive tobacco exposure: A serious pediatric health problem. A statement from the Committee on Atherosclerosis and Hypertension in Children, Council on Cardiovascular Disease in the Young, American Heart Association, Circulation, 90, pp. 2581-2590, (1994)
  • [10] William C.L., Hayman L.L., Daniels S.R., Et al., Cardiovascular health in childhood: A statement for health professionals from the Committee on Atherosclerosis, Hypertension, and Obesity in the Young (AHOY) of the Council on Cardiovascular Disease in the Young, American Heart Association, Circulation, 106, pp. 143-160, (2002)